The Wellcome Trust has given the company, called Population Genetics Technologies, a £1.1 million ($2.1 million) Programme Related Investment grant to help it start developing the technology. The money will appear as soon as the company receives "additional" venture capital funding, the Wellcome Trust added.
It was not immediately clear how much private-equity financing the company has so far received, or from whom.
The intellectual property and related patent applications underlying the technology were licensed from Compass Genetics, a partnership formed several years ago by Brenner; Sam Eletr, a current director at Third Wave Technologies and former director at Solexa and Lynx Therapeutics; and Philip Goelet, director of Red Abbey Venture Partners, a UK-based private-equity firm. Additional information about the platform was not disclosed.
Population Genetics Technologies will be located in